Neoadjuvant radiotherapy combined with and without "T+A" regimen in the treatment of resectable hepatoma with portal vein cancer thrombolus : a prospective randomized controlled study

Neoadjuvant radiotherapy combined with and without "T+A" regimen in the treatment of resectable hepatoma with portal vein cancer thrombolus: a prospective randomized controlled study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072234

Enrollment

Unknown

Registered

2023-06-07

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

group A:Radical surgical excision after neoadjuvant radiotherapy combined with "T+A" regimen

group A:Radical surgical excision after neoadjuvant radiotherapy without "T+A" regimen

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Patients voluntarily joined the study and signed informed consent; 2). Between the ages of 18 and 75, regardless of gender; 3) The diagnosis was confirmed as primary hepatocellular carcinoma; 4) The primary liver tumor can be radically resected; Cheng's classification of portal vein cancer suppository (Type II/III); 5). Liver function Child A; 6) Functional tolerance surgery of vital organs. 7) Gastroscopy esophageal veins without severe varicosity, no active digestive tract ulcer. 8). Hemoglobin =90g/L, white blood cell count =3.0×10^9/L, neutrophil count =1.5×10^9/L, platelet count =60×10^9/L, no definite cachexia;

Exclusion criteria

Exclusion criteria: 1) Local treatment of portal vein cancer thrombus was performed before admission (including intra portal chemotherapy, portal metal stent implantation, intra portal particle implantation and external portal radiotherapy). 2) The tumor has developed distant metastasis, such as metastasis of lung, brain, bone, etc 3) Imaging suggested the formation of hepatic vein and vena cava cancer thrombus. 4) Severe varicose esophagus and gastric fundus veins, prone to gastrointestinal bleeding, or previous history of massive gastrointestinal bleeding; 5) History of other malignant tumors within 5 years; 6) Heart, lung and renal insufficiency. Oral administration of warfarin and other anticoagulant drugs within 2 weeks. 7) Researchers believe that participants should not participate in this study for other reasons.

Design outcomes

Primary

Measure	Time frame
Survival time;	—

Secondary

Measure	Time frame
Disease-free survival time;	—

Countries

China

Contacts

Public Contactchongde Lu/ shuqun Cheng

Eastern Hepatobiliary Surgery Hospital

86246337@qq.com+86 021 81887581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026